Efficacy and safety of low-power holmium laser enucleation of the prostate: experience gained from more than 700 cases
Abstract
Background/aim The aim of this study was to investigate the functional outcomes, safety, and effectiveness of low-power (LP) holmium laser enucleation of the prostate (HoLEP) using a 37.5 W holmium laser source. Materials and methods We retrospectively reviewed 713 patients with a diagnosis of benign prostatic hyperplasia (BPH) treated with HoLEP using an LP setting (37.5 W laser set to 1.5 J with a frequency of 25 Hz). All procedures were performed by experienced urologists. Functional outcomes, perioperative parameters, and complications were assessed over a 12-month follow-up period. Effect sizes (Cohen’s d) and 95% confidence intervals (CI) were calculated to evaluate the magnitude and precision of changes in maximum urinary flow rate (Qmax), postvoiding residual volume (PVR), international prostate symptoms score (I-PSS), and other parameters. Results The mean (SD) preoperative serum PSA level was 4.8 ng/mL (3.6), and the mean prostate volume was 94.02 mL (55.35). The average enucleation time was 72.42 min (32.36), morcellation time was 10.35 min (8.62), and total operation time was 82.74 min (38.08). At 1 month after the surgery, significant improvements were observed in I-PSS (from 25.01 (7.62) to 11.02 (5.3), Cohen’s d = 2.08, 95% CI 1.91–2.25), Qmax (from 10.7 (4.28) to 18.68 (9.52) mL/s, d = 1.08, 95% CI 0.93–1.22), and PVR (from 139.38 (18.07) to 24.85 (18.07) mL, d = 3.13, 95% CI 2.87–3.39), all with p < 0.001. Transfusion was required in 23 patients (3.2%) and…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.